Research of genetic cardiovascular diseases has lacked of good disease models because rodents, which are primarily used, differ greatly from humans. The ability to derive human induced pluripotent stem cells (hiPSCs) from patients carrying inherited cardiac diseases has revolutionized research in the cardiovascular field. The aim for this chapter is to review the current hiPSC reprogramming methods and methods for differentiating human pluripotent stem cells (hPSCs) into cardiomyocytes. The chapter focuses on the published hiPSC models for hypertrophic cardiomyopathy (HCM) and discusses the challenges related to modeling this interesting disease using hiPSC technology.

While most stem cell books focus on basic aspects and/or cell therapy, this book emphasizes the relevance of stem cells obtained from patients, the so-called “patients in a petri dish” as tools to investigate human genetic diseases for which there are no available effective treatment. Chapters embrace several examples of the use of iPS cell technology, a recent Nobel Prize-winning scientific breakthrough, to obtain patient-specific pluripotent cells from which many types of specialized cells involved in a particular disease can be generated, including psychiatric and neurodegenerative disorders, muscular dystrophies, laminopathies, among others. The text is a current and timely resource for postgraduate students, scientists and clinicians, interested in applications of this rapidly developing field of research in disease modeling, drug development, and emerging issues that it brings to regenerative medicine.

Doxorubicin (DOX) has been used for decades to treat hematopoietic and solid tumors, although, in a subset of cancer survivors, it causes cardiotoxicity decades after treatment. The mechanisms of anthracycline-induced cardiotoxicity (ACT) are still incompletely understood. Induced pluripotent stem cells (iPSCs)-derived cardiomyocytes have become a valuable tool to study hereditary and structural cardiac conditions in vitro. A former study from our group showed that iPSC-derived cardiomyocytes (iPSC-CMs) from lymphoma patients with ACT were continuously more sensitive to DOX toxicity, demons...

Pluripotent stem cells have distinct characteristics: self-renewal and the potential to differentiate into various somatic cells. In recent years, substantial advances have been made from basic science to clinical applications. The vast amount knowledge available makes obtaining concise yet sufficient information difficult, hence the purpose of this book. In this book, embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells are discussed. The book is divided into five sections: pluripotency, culture methods, toxicology, disease models, and regenerative medicine. The topics covered range from new concepts to current technologies. Readers are expected to gain useful information from expert contributors.

This detailed volume presents a series of protocols that are representative of recent developments and improvements in induced pluripotent stem cells (iPS cells) and corresponding human disease models. Reflecting the latest technology for generating induced pluripotent stem cells (iPS cells) and their initial characterization, the book explores techniques invaluable both for studies of disease-specific cell types and for their potential applications in regenerative medicine. Written for the highly successful Methods in Molecular Biology series, chapters include introduction to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, as well as tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Induced Pluripotent Stem Cells and Human Disease: Methods and Protocols serves as a vital guide that is valuable for not only experts but also novices in the stem cell field.

This volume highlights recent advances using iPS cells in disease modeling and medical applications along with new technologies that enhance the power of iPS cells. While the discovery of iPS cells has provided excellent opportunities for developing models of human diseases, platforms for drug discovery and cell therapies, iPS cell technology still faces many challenges. Presenting the latest advances in this rapidly evolving research area, this book is intended to widen the community of researchers and clinicians interested in the exciting field of iPS cells.